The Jan Twomey story — Empowering and connecting
Earlier this year Jan had a big decision to make. In her early 60s, she could leave pharma and pursue her dream to join the crew on the Mercy ship – serving patients in need around Africa - or stay with Takeda through their transition and lead the Medical team for Oceania. She chose to stay and here’s why. “It gives me a lot of pleasure helping my team to be happy and thrive,” says Jan. Jan was raised to really think about society and people. Her father encouraged vigorous debate, pushing Jan to defend her beliefs and statements. As a child of the 70’s, Jan was on a mission to change the world and started by...
Source: EyeForPharma - September 6, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
MSL webinar
Channels: MedicalImage: URL: https://www.eyeforpharma.com/barcelona/webinar2/?partner=efp-website-listing&utm_source=efp%20website&utm_medium=efp%20websiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - September 4, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
No patents. No launches. No stages. Welcome to modern pharma.
It ’s not enough to have a customer experience strategy, give it a little funding, and hope it somehow takes off. Companies outside of healthcare that are winning in experience treat it like a core product.
That means they have a senior leader overseeing a team and full P&L dedicated to the success of that experience, both the overall and micro-moments. What is keeping pharma companies from doing this? If you follow the money, things become clear. Traditional confines based on milestone dates put a tremendous amount of stress on an organization to maximize its investments in a finite window of time....
Source: EyeForPharma - September 3, 2019 Category: Pharmaceuticals Authors: Anonymous Source Type: news
Whose Data is it Anyway?
When cancer patient Pete started to look into who held records about his illness and treatment, mapping the journey of his data proved to be no easy feat. Tracking where his information was held, had been used, and might yet be used in the future took tens of hours of searching and filing requests.
As a member of use MY data, a UK-based patient group working to build confidence in the use of healthcare data, he is helping to demonstrate how much work the industry has to do when it comes to transparency around patient data.
This lack of accessibility, coupled with the wider suspicion around data usage thanks...
Source: EyeForPharma - August 30, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of clinical tria...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of clinical tria...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of clinical tria...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Unleashing AI ’s potential in clinical trial recruitment
The onerous cost of clinical trials in time, money and effort is well documented. The average clinical trial process lasts between 7.5 and 12 years, studies estimate, with costs ranging from $161M - $2.6B per drug. Just 14% of clinical trials are successful and only one in ten drugs entering Phase 1 ends up being approved by the FDA. Recruitment is a significant source of the problem. According to Christina Busmalis, director of global life sciences at IBM Watson Health,80% of clinical trials do not finish on time and the reason for this, in 86% of cases, is that they do not meet target recruitment on time. “It’s a...
Source: EyeForPharma - July 29, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Making it about the patient, with the patient
While attending a recent eyeforpharma conference, the words of one particular speaker stuck with Laurie Meyers.“There was a patient who spoke and said something that struck me to the core. He said, ‘if you do it without us, then it’s not about us’. Those words said it all for me, for Genentech, and for all of our industry partners,” says Meyers. “We must involve patients early and often in co-cre ating and ideating on solutions meant for them.”Genentech was already working to engage with patients in a more meaningful way before she heard this speaker but his observation has since become a ‘north star’ for...
Source: EyeForPharma - July 26, 2019 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news
The Tausif ‘Tosh’ Butt Story –Different lenses, different lessons
“Sometimes you need to see things from a different lens,” says Tosh Butt (SVP in Latin Am and Brazil for AstraZeneca). That different lens has been in Tosh’s back pocket throughout his life and is helping him better serve his team and the doctors and patients they serve. Read on to hear how the different lenses from three experiences (a handbag factory, Paula and a newspaper clipping) changed Tosh’s story. Thank you Tosh. We are so grateful you brought your wisdom and passion to our industry. You are truly a purpose-driven, inspirational leader! 3 lenses that shaped Tosh ’s life:1.Handbag factoryBorn in Pakis...
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Cue Biopharma: Diagnostic & disease detection to transform biopharma
Pr écis: How Cue BioPharma is taking the next leap in drug discovery and focusing on diagnostic and detection. Anish Suri, Chief Scientific Officer, speaking on the keynote stage at eyeforpharma PhiladelphiaYouTube URL: https://www.youtube.com/watch?v=X4kBSMt_7KUVideo Thumbnail Image: Channels: MedicalMultichannelPatients and MedicalClinicalTags: preventative medicine (Source: EyeForPharma)
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Dr Avi Spira: Janssen's use of new technology to intercept lung cancer
Pr écis: Dr Avi Spira, Global Head of Johnson& Johnson's Lung Cancer Initiative on their use of ML, Robotics and Molecular Technology to intercept lung cancer.YouTube URL: https://www.youtube.com/watch?v=oe5T5RF1Z3EVideo Thumbnail Image: Channels: Access and EvidenceMedicalTags: Janssen (Source: EyeForPharma)
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
The Eisenbahnscheinbewegung Risk
Pr écis: Kris Sterkens, Company Group Chairman, Europe, Middle East and Africa at Janssen speaking on the closing keynote stage at eyeforpahrma Barcelona 2019.YouTube URL: https://www.youtube.com/watch?v=rKp04QLrkQgVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalTags: Janssen (Source: EyeForPharma)
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Up Close and Personal: The Naji Gehchan Story – On a mission to improve life
From the moment I met Naji Gehchan, I loved his positive energy. Later when I learned of his path that developed that energy, I appreciated it even more. Naji has never shared this story, until now. Read how a childhood avoiding bombs, the Red Cross and a chance internship created the man he is today. He is living a mission to improve as many lives as possible – both inside and outside his organization.
A few years ago, Naji was sitting in a workshop at Disney University in Orlando. As an icebreaker, the facilitator asked each participant for their first childhood memories. One after another, people talked of Mickey...
Source: EyeForPharma - July 8, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Up Close and Personal – The Bill Strickland Story
Bill Strickland ' s (Head of Global Medical Resources at AstraZeneca) aptitude for science came naturally. His father taught Chemical Engineering at the University of Arkansas and his mother was an Ultrasonographer He loved complex problems and had an eye to see opportunities and make improvements. His mom always said he was the “but why” kid. How do you get someone to the moon? How do you cure cancer? Bill wanted to know.
Between the ‘puzzling’ and games they played as a family to test their minds and the incredible stories his mom brought home from the hospital; Bill was hooked on solving the problems in med...
Source: EyeForPharma - June 27, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
